Search

Your search keyword '"Bortolotti F."' showing total 889 results
Start Over Author "Bortolotti F."
889 results on '"Bortolotti F."'

3. Recommendations on the measurement and use of the alcohol consumption biomarker CDT. A position paper from the IFCC Working Group on CDT standardisation

Author

Wielders, J.P.M., primary, Porpiglia, N.M., additional, Schellenberg, F., additional, Deenmamode, J., additional, Delanghe, J., additional, Anton, R.F., additional, Bortolotti, F., additional, Siebelder, C., additional, Tagliaro, F., additional, Weykamp, C., additional, and Helander, A., additional

Published
2024
Full Text
View/download PDF

8. List of Contributors

Author

Al-Mohanna, F., primary, Bartlett, J., additional, Bortolotti, F., additional, Charles, C.J., additional, Chatha, K., additional, Ciccarelli, M., additional, Coscioni, E., additional, De Mello, W.C., additional, Iaccarino, G., additional, Kangawa, K., additional, Karmazyn, M., additional, Kuwahara, K., additional, Kyrou, I., additional, Ledee, D., additional, Lymperopoulos, A., additional, Mattu, H.S., additional, Nakagawa, Y., additional, Nakao, K., additional, Nishikimi, T., additional, Parry, T., additional, Pemberton, C.J., additional, Portman, M.A., additional, Pulinilkunnil, T., additional, Randeva, H.S., additional, Ranek, M.J., additional, Recchia, F.A., additional, Richards, A.M., additional, Ruozi, G., additional, Samson, W.K., additional, Santulli, G., additional, Sorriento, D., additional, Stein, L.M., additional, Trivedi, P., additional, Vu, A., additional, Willis, M.S., additional, and Yosten, G.L.C., additional

Published
2017
Full Text
View/download PDF

10. Flurbiprofen sodium microparticles and soft pellets for nose-to-brain delivery: Serum and brain levels in rats after nasal insufflation

Author

Tiozzo Fasiolo, L. Manniello, M.D. Banella, S. Napoli, L. Bortolotti, F. Quarta, E. Colombo, P. Balafas, E. Kostomitsopoulos, N. Rekkas, D.M. Valsami, G. Papakyriakopoulou, P. Colombo, G. Russo, P.

Abstract

Neuroinflammation in Alzheimer's disease (AD) revamped the role of a preventive therapeutic action of non steroidal anti-inflammatory drugs; flurbiprofen could delay AD onset, provided its access to brain is enhanced and systemic exposure limited. Nasal administration could enable direct drug access to central nervous system (CNS) via nose-to-brain transport. Here, we investigated the insufflation, deposition, dissolution, transmucosal permeation, and in vivo transport to rat brain of flurbiprofen from nasal powders combined in an active device. Flurbiprofen sodium spray-dried microparticles as such, or soft pellets obtained by agglomeration of drug microparticles with excipients, were intranasally administered to rats by the pre-metered insufflator device. Blood and brain were collected to measure flurbiprofen levels. Excipient presence in soft pellets lowered the metered drug dose to insufflate. Nevertheless, efficiency of powder delivery by the device, measured as emitted fraction, was superior with soft pellets than microparticles, due to their coarse size. Both nasal powders resulted into rapid flurbiprofen absorption. Absolute bioavailability was 33% and 58% for microparticles and pellets, respectively. Compared to intravenous flurbiprofen, the microparticles were more efficient than soft pellets at enhancing direct drug transport to CNS. Direct Transport Percentage index evidenced that more than 60% of the intranasal dose reached the brain via direct nose-to-brain transport for both powders. Moreover, remarkable drug concentrations were measured in the olfactory bulb after microparticle delivery. Bulb connection with the entorhinal cortex, from where AD initiates, makes flurbiprofen sodium administration as nasal powder worth of further investigation in an animal model of neuroinflammation. © 2021 Elsevier B.V.

Published
2021

14. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome

Author

Bortolotti, F., Resti, M., Marcellini, M., Giacchino, R., Verucchi, G., Nebbia, G., Zancan, L., Marazzi, M.G., Barbera, C., Maccabruni, A., Zuin, G., Maggiore, G., Balli, F., Vajro, P., Lepore, L., Molesini, M., Guido, M., Bartolacci, S., and Noventa, F.

Subjects
Hepatitis C virus -- Research, Genotype -- Research, Children -- Diseases, Children -- Research, Health
Published
2005

36. Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer’s disease

Author

Tiozzo Fasiolo, L. Manniello, M.D. Bortolotti, F. Buttini, F. Rossi, A. Sonvico, F. Colombo, P. Valsami, G. Colombo, G. Russo, P.

Abstract

Neuroinflammation occurs in the early stages of Alzheimer's disease (AD). Thus, anti-inflammatory drugs in this asymptomatic initial phase could slow down AD progression, provided they enter the brain. Direct nose-to-brain drug transport occurs along olfactory or trigeminal nerves, bypassing the blood-brain barrier. Nasal administration may enable the drug to access the brain. Here, flurbiprofen powders for nose-to-brain drug transport in early AD-related neuroinflammation were studied. Their target product profile contemplates drug powder deposition in the nasal cavity, prompt dissolution in the mucosal fluid and attainment of saturation concentration to maximise diffusion in the tissue. Aiming to increase drug disposition into brain, poorly soluble flurbiprofen requires the construction of nasal powder microparticles actively deposited in nose for prompt drug release. Two groups of powders were formulated, composed of flurbiprofen acid or flurbiprofen sodium salt. Two spray dryer apparatuses, differing for spray and drying mechanisms, and particle collection, were applied to impact on the characteristics of the microparticulate powders. Flurbiprofen sodium nasal powders disclosed prompt dissolution and fast ex vivo transport across rabbit nasal mucosa, superior to the acid form, in particular when the powder was prepared using the Nano B-90 spray dryer at the lowest drying air temperature. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

Published
2019

48. Effects of mandibular advancement device for obstructive sleep apnea on temporomandibular disorders: A systematic review and meta-analysis

Author

Alessandri-Bonetti, A., Bortolotti, F., Moreno-Hay, I., Michelotti, A., Cordaro, Massimo, Alessandri-Bonetti, G., Okeson, J. P., Cordaro M. (ORCID:0000-0002-0797-5172), Alessandri-Bonetti, A., Bortolotti, F., Moreno-Hay, I., Michelotti, A., Cordaro, Massimo, Alessandri-Bonetti, G., Okeson, J. P., and Cordaro M. (ORCID:0000-0002-0797-5172)

Abstract

The clinical practice guidelines do not give precise indications on the use of mandibular advancement devices (MAD) for obstructive sleep apnea (OSA) patients when they suffer from temporomandibular disorders (TMD). The aim of this systematic review was to evaluate the effects of MADs on prevalence of TMD signs and symptoms in adult OSA patients. The study protocol was registered under the PROSPERO register and an electronic search was performed in several databases. All types of studies evaluating TMD prevalence on adult patients wearing MAD for OSA were included and independently evaluated by two investigators. The quality of evidence was evaluated using the grading of recommendations assessment, development and evaluation and the risk of bias by the risk of bias in non-randomized studies of interventions tool or the Cochrane collaboration's tool. For each study included, the difference in means and 95% CI was calculated between baseline and follow-up. Twelve studies were included. The meta-regression analysis showed that patients with pre-existing signs and symptoms of TMD do not experience significant exacerbation of symptoms using the MAD. The presence of TMD does not appear to be routine contraindication for the use of MAD used for the management of OSA.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results